Substance Use Screening for People with HIV

(ePORTAL-HIV-S Trial)

DZ
NC
Overseen ByNeNe Clark
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Chicago
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to improve the screening and treatment of substance use disorders for Black individuals living with HIV. It tests a new approach called ePORTAL HIV-S, which uses a patient portal to provide a quick substance use screener, even without a scheduled visit with an HIV doctor. The trial compares this method to the usual care, where screening occurs only during scheduled appointments. Individuals who have HIV, speak English, and haven't had a substance use screening at their clinic in the past year might be a good fit for this study. As an unphased trial, this study offers a unique opportunity to contribute to innovative healthcare solutions.

Do I need to stop my current medications for this trial?

The trial protocol does not specify whether you need to stop taking your current medications.

What prior data suggests that the ePORTAL HIV-S program is safe for substance use screening in people with HIV?

Research has shown that the ePORTAL HIV-S treatment aims to include substance use screening as part of HIV care, marking a relatively new approach in standard HIV treatments. The treatment employs a system called ePORTAL, which has been linked to better outcomes in managing HIV. Studies have found that individuals using patient portals to manage their health are more likely to maintain control over their HIV.

Specific safety data for ePORTAL HIV-S is not available, but the trial is marked as "Not Applicable" for its phase. This likely indicates that the treatment involves non-invasive methods like screenings and referrals, which are generally safe. Additionally, patient portals are widely used in healthcare and are well-tolerated, suggesting that the ePORTAL HIV-S treatment should be safe and manageable for participants.12345

Why are researchers excited about this trial?

Researchers are excited about the Substance Use Screening for People with HIV trial because it explores a new way to identify substance use issues among HIV patients. Unlike the standard approach, which screens patients only during scheduled HIV clinic appointments, this trial uses an innovative method of delivering the NIDA Quick Screen via a patient portal. This means patients can be screened at any time, not just during appointments, potentially catching substance use problems earlier and more efficiently. This proactive approach could lead to timely interventions, better overall health outcomes, and improved quality of life for people living with HIV.

What evidence suggests that this trial's treatments could be effective for substance use disorder screening in people with HIV?

Research has shown that combining substance use services with HIV care can improve health outcomes. In this trial, the ePORTAL HIV-S treatment is being tested to identify and treat substance use problems among Black people living with HIV. Studies suggest that using a patient portal for screening can facilitate access to necessary care, promoting fairer access to substance use treatment. By monitoring patients even without appointments, ePORTAL HIV-S aims to detect issues early and provide timely assistance. This method has shown promise in enhancing health outcomes through quick interventions. Meanwhile, another group in this trial will receive usual care substance use involvement screening during scheduled appointments, allowing for a comparison of these approaches.12367

Who Is on the Research Team?

JP

Jessica P. Ridgway, MD

Principal Investigator

University of Chicago

NL

Neda Laiteerapong, MD, MS

Principal Investigator

University of Chicago

Are You a Good Fit for This Trial?

This trial is for Black individuals living with HIV who may also be dealing with drug addiction or substance use disorders. Participants should be comfortable using a patient portal for health screenings and not currently enrolled in other SUD treatment studies.

Inclusion Criteria

Provider has assented
Speaks English
I have been diagnosed with HIV.
See 3 more

Exclusion Criteria

Patients who have been screened for substance use disorder at the clinic in the last year using the NIDA Quick Screen
Patient's provider has not assented to the intervention
I am under 18 years old.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person) or via patient portal

Treatment

Participants receive referral-focused treatment for substance use disorder

1 year
Clinic-based treatment visits

Follow-up

Participants are monitored for retention in care and HIV viral suppression

1 year
Regular clinic visits

Long-term Follow-up

Participants are monitored for retention in care in the year post-screening

2 years

What Are the Treatments Tested in This Trial?

Interventions

  • ePORTAL HIV-S
  • Usual Care Substance Use Involvement Screening
Trial Overview The study tests if a population-level patient portal can improve substance use disorder screening over the usual care methods in an HIV clinic setting. It's a randomized control trial, meaning people are put into groups by chance to compare outcomes.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Usual Care SUD ScreeningExperimental Treatment1 Intervention
Group II: Patient portal population level substance involvement risk screenerExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Chicago

Lead Sponsor

Trials
1,086
Recruited
844,000+

National Institute on Drug Abuse (NIDA)

Collaborator

Trials
2,658
Recruited
3,409,000+

Published Research Related to This Trial

A survey of 286 HIV care sites in 45 countries showed that from 2014-2015 to 2017, there was a notable increase in the provision of substance use education (up 9%), screening (up 16%), and referrals (up 8%) for patients, indicating a positive trend in integrating substance use services into HIV care.
Despite these improvements, significant gaps remain, especially in screening and referral services for children and adolescents, and in lower-income countries, highlighting the need for continued efforts to enhance these services in resource-constrained settings.
Substance use service availability in HIV treatment programs: Data from the global IeDEA consortium, 2014-2015 and 2017.Parcesepe, AM., Lancaster, K., Edelman, EJ., et al.[2023]

Citations

1.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/40927331/
Protocol for a randomized controlled trial of patient-portal ...Protocol for a randomized controlled trial of patient-portal-based screening for substance use among people with HIV. Front Public Health ...
Achieving Equity in Patient Outcome Reporting for Timely ...This study aims to achieve health equity in substance use disorder (SUD) screening and treatment among Black people living with human immunodeficiency virus ...
Protocol for a randomized controlled trial of patient–portal– ...... HIV and Substance Use (ePORTAL HIV-S) study (1R01DA058965). The study seeks to achieve health equity in SUD screening and treatment among Black adults ...
Protocol for a randomized controlled trial of patient–portal– ...... HIV and Substance Use (ePORTAL HIV-S) study (1R01DA058965). The study seeks to achieve health equity in SUD screening and treatment among Black adults ...
Substance Use Screening for People with HIV (ePORTAL ...Integrating substance use services into HIV care has been shown to improve patient outcomes, suggesting that treatments like ePORTAL HIV-S could be effective in ...
Protocol for a randomized controlled trial of patient–portal ...The primary outcome will be the percentage of people screened for substance use. ePORTAL will also implement a collaborative care model to both ...
Association Between Electronic Patient Portal Enrollment ...In multivariable models, people with HIV with an active portal account had higher odds of HIV viral suppression (Odds Ratio [OR]: 2.02, 95% CI [ ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security